

#### AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application.

#### Listing of Claims

1. (Currently amended) A stabilized pharmaceutical composition comprising fibroblast growth factor (FGF) or variant thereof, glycine and ~~at least one reducing agent~~ dithiothreitol (DTT) in an amount sufficient to inhibit oxidation of said FGF or variant thereof, wherein said glycine is present at a concentration of about 0.5% to about 5%, and wherein cysteine residues in said growth factor need to be maintained in a reduced state.
2. (Original) The composition of claim 1, wherein said FGF lacks any disulfide bonds.
3. (Original) The composition of claim 1, wherein said composition is a liquid formulation.
4. (Original) The composition of claim 1, wherein said composition is a lyophilized formulation.
5. (Original) The composition of claim 1, wherein said FGF is FGF-2.
6. (Original) The composition of claim 5, wherein said FGF-2 includes any biologically active fragment or variant of FGF-2.
7. (Original) The composition of claim 5, wherein said FGF-2 is recombinant FGF-2.
- 8.-9. (Canceled)
10. (Currently amended) The composition of claim ~~[[9]]~~ 1, wherein said composition has a hemolytic potential of less than about 10%.

11. (Original) The composition of claim 1, wherein said composition has a pH within the range of about pH 3.0 to about pH 7.5.
12. (Original) The composition of claim 11, wherein said composition has a pH within the range of about pH 5.5 to about pH 6.5.
13. (Currently amended) The composition of claim [[9]] 1, wherein said DTT is present at a concentration of about 0.1 mM to about 10 mM.
14. (Currently amended) The composition of claim [[9]] 23, wherein said n-acetyl-cysteine is present at a concentration of about 0.5%.
15. (Withdrawn) A method for increasing stability of FGF or variant thereof in a pharmaceutical composition, said method comprising incorporating into said composition a reducing agent in an amount sufficient to inhibit oxidation of said FGF or variant thereof.
16. (Withdrawn) The method of claim 15, wherein said FGF is FGF-2.
17. (Withdrawn) The method of claim 16, wherein said FGF-2 is recombinant FGF-2.
18. (Withdrawn) The method of claim 15, wherein said reducing agent is a thiol derivative.
19. (Withdrawn) The method of claim 18, wherein said thiol derivative is selected from the group consisting of dithiothreitol (DTT), n-acetyl-cysteine, or a combination thereof.
20. (Withdrawn) The method of claim 15, wherein said composition has a pH of about pH 3.0 to about pH 7.5.
21. (Withdrawn) The method of claim 20, wherein said composition has a pH of about pH 5.5 to about pH 6.5.

22. (Withdrawn) A method for increasing storage stability of a pharmaceutical composition comprising FGF or variant thereof, where said FGF or variant thereof becomes oxidized during storage, said method comprising incorporating into said composition a reducing agent in an amount sufficient to inhibit oxidation of said FGF or variant thereof.
23. (New) The composition of claim 1, further comprising n-acetyl-cysteine.